SCHEMBL279607

SCHEMBL279607

Cc1ccc(C(=O)N2CC(O)C(O)C2)s1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.55
ALDH1A1 P00352 5/20 0.55
DAO P14920 1/20 0.48
SLC18A3 Q16572 3/20 0.47
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL3 Q96JM7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
YEATS4 O95619 1/20 0.41
POLB P06746 2/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279900 0.87 HPGD (0.47) HPGDALDH1A1DAOSLC18A3LMNA
SCHEMBL29965097 0.82 HPGD (0.49) HPGDALDH1A1DAOSLC18A3LMNA
SCHEMBL21336759 0.82 SMN1; SMN2 (0.60) HPGDALDH1A1DAOLMNAGAA
SCHEMBL27387680 0.82 ALDH1A1 (0.58) HPGDALDH1A1DAOSLC18A3LMNA
SCHEMBL19012369 0.82 SMN1; SMN2 (0.60) HPGDALDH1A1DAOLMNAGAA
SCHEMBL279692 0.82 HPGD (0.51) HPGDALDH1A1DAOSLC18A3LMNA
SCHEMBL14625164 0.81 HPGD (0.57) HPGDALDH1A1DAOSLC18A3LMNA
SCHEMBL29964064 0.80 HPGD (0.49) HPGDALDH1A1DAOSLC18A3LMNA
SCHEMBL13006693 0.79 HPGD (0.39) HPGDALDH1A1DAONPC1RAB9A
SCHEMBL12313642 0.79 HPGD (0.68) HPGDALDH1A1LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20100310536-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2010-12-09 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HPGD 1895/4885ALDH1A1 2047/4885DAO 1673/4885
US-20100310536-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND HCLS1, CD44, NES HPGD 884/4885ALDH1A1 186/4885DAO 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.